Purpose: To identify the proportion of older adults with a high anticholinergic/sedative load and to identify patient subgroups based on type of central nervous system (CNS)-active medication used.
| INTRODUCTION
Despite their adverse effects on physical and cognitive function, 1, 2 anticholinergic and sedative medications are frequently prescribed to older patients. 3, 4 Some medications are deliberately prescribed for their anticholinergic or sedative effect, for example, inhaled anticholinergics for chronic airway diseases or benzodiazepines for insomnia.
However, for most medications, the anticholinergic/sedative effect is a side effect. 5 Anticholinergic/sedative medications mostly act on the central nervous system (CNS) and include psycholeptics, psychoanaleptics, and analgesics. 6 So far, most research has focused on quantifying the cumulative exposure of multiple anticholinergic/sedative medications in older patients with polypharmacy. 7 Little is known about the prevalence of combinations of multiple anticholinergic/sedative medications resulting in a high load or whether subgroups of these patients based on types of anticholinergic/sedative medications used can be identified.
Latent class analysis (LCA) is a person-centred approach, which identifies underlying patterns within populations that cannot be directly measured or observed. 8 In a population of older adults having a high anticholinergic/sedative load, LCA has the potential to identify subgroups of patients based on specific medication patterns or types of anticholinergic/sedative medications used. This is a novel approach to investigate medication use. In this study, we will firstly determine the proportion of older adults having a high cumulative anticholinergic/sedative load, and secondly, we will perform an LCA to identify subgroups of patients based on the most likely type of CNS-active medications used.
| METHODS

| Study design and setting
A cross-sectional study on a nationwide sample of patients with pre- using at least one anticholinergic/sedative medication in the study period. The SFK collects exhaustive data about medications dispensed by more than 95% of all community pharmacies in the Netherlands. 9 Dutch community pharmacies keep complete electronic medication records of their patients, and patients usually register with a single pharmacy for medication supply (a closed pharmacy system).
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Our data therefore provide a good approximation of patients' overall medication use.
| Anticholinergic and sedative load
Anticholinergic/sedative medication load was quantified with the drug burden index (DBI). 11 Previous studies have identified that a higher DBI was associated with an increased risk of medication harm among older populations. 12 The DBI was calculated using the following formula:
where D = prescribed daily dose and δ = the minimum recommended daily dose according to Dutch pharmacotherapeutic reference sources. 13, 14 All prescription medications dispensed by the pharmacy with mild or strong anticholinergic and/or sedative (side) effects with a usage date in the study period (1 month) were included in the DBI calculation. Medications without known prescribed daily dose and preparations for which daily dose could not be determined were excluded from the DBI calculation. These comprised dermatological, gastro enteral, nasal, rectal, and vaginal preparations, oral fluids, oral and sublingual sprays, oral drops, parenteral medications and "as needed" medications. Our database did not include data of medications dispensed "over the counter".
We included all medications classified as anticholinergic by Duran et al. 6 Then, we systematically reviewed all other medications used in the Netherlands and included those with anticholinergic or sedative properties and those with frequently reported sedative side effects reported in Dutch pharmacotherapeutic reference sources. 13, 14 Following the formula above, the DBI per medication ranged between 0 and 1, depending on the prescribed daily dose. If the prescribed daily dose was similar to the minimum recommended daily dose, the DBI for that medication would be 0.5. In our study, we include patients with a DBI greater than 1. A DBI above this threshold was considered a high anticholinergic/sedative load.
| Study population
All older adults, aged older than 65 years, with a high anticholinergic/sedative load, that is a DBI greater than 1, were identified from medication dispensing records and included in the study.
We excluded 16 498 patients (2.1% of all patients) from 32 pharmacies (1.8% of all pharmacies in database) using a pharmacy
KEY POINTS
• A large proportion of older community-dwelling patients in the Netherlands had a high load of anticholinergic/ sedative medication.
• According to the type of CNS-active medications used, four distinct patient subgroups with high anticholinergic/sedative loads were identified using latent class analysis.
• Interventions aiming at reducing the cumulative anticholinergic/sedative load can be targeted to these patient subgroups.
information system with a specific software package, as this software was known for reporting errors in dispensing dates. We also excluded 868 patients with unknown gender and/or age or reported age older than 110 years (0.11%).
| Data source
The dataset contained demographic patient data that were collected by SFK, such as anonymous patient identification code, age, gender, anonymous pharmacy code, and medication data including generic name, daily defined dose, preparation form, and World Health Organization Anatomical Therapeutic Chemical (ATC) code (2016). 
| Outcomes and statistics
The proportion of older adults having a high anticholinergic/sedative load was calculated by dividing the number of individuals in our study population by the number of older adults (aged ≥65 years) who were dispensed at least one medication with a usage date within the study period from one of the community pharmacies included in our study. The LMR tested whether the current model with n-classes was better than the previous model with n-1 classes. Improvement was deemed significant if the associated p value was less than 0.05. Higher entropy,
which is a quality indicator of classification ranging from 0 to 1, indicated a better classification. Entropy values greater than 0.8 were acceptable. To identify clinically relevant classes, alongside goodness of fit, we only considered models with patient subgroups (classes) that consisted of at least 5% of the study population. 8 As convergence of local solutions is a common issue of LCA, we increased the number of random starts when necessary to get global solutions. We fixed thresholds of parameter estimates to the observed probabilities if necessary. Following these criteria above, we identified the best fitting model with n-classes and subsequently assigned patients to their most likely class based on model probabilities. Demographic descriptives of all patients and of patients within each class were derived in the Sta- Table 2 ).
The four patient subgroups (classes) were described after their most likely type of CNS-medications used, namely, "combined psycholeptic/psychoanaleptic medication" (class 1, 57.9%), "analge- Table S1 .
| DISCUSSION
| Key findings
Nearly one in 10 Dutch older adults using medications had a high anticholinergic/sedative load. We identified four subgroups (classes)
of patients based on their most likely used type of CNS-active medications, described as patients using combined psycholeptic/psychoanaleptic medication, analgesics, antiepileptic medication, and patients using anti-Parkinson medications.
| Strengths and limitations
This was an innovative study identifying patients with high anticholinergic/sedative loads and providing insight into the type of medication contributing to this high load in individual patients. A key 
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Furthermore, antiepileptic medications are prescribed for behavioural disorders. 20 Within the group of antiepileptic medication users, we therefore could not distinguish between patients with epilepsy, neuropathic pain, or behavioural disorders. Finally, there is no international consensus about which medications have anticholinergic/sedative properties. 21 A first attempt has been the systematic review on anticholinergic medications where we based our list of anticholinergic medications on. 6 For sedative medications, this is lacking. While anticholinergic effects are a result of muscarinic receptor blocking, 5 different pharmacological pathways lead to sedation, of which most pathways are still unknown. 22 Therefore, we based our list of sedative medications on a systematic analysis of relevant frequently reported (side) effects in relevant reference sources. More work needs to be done, to come to an evidence-based list of medications. This may limit the comparability of studies using the DBI. 23 
| Interpretations and other studies
We found that in the population of Dutch older adults using medications, about one third used at least one anticholinergic/sedative medication and one in 10 had a high anticholinergic/sedative load. This is in line with other studies, 26, 27 but exact numbers are difficult to compare because of differences in study populations and definitions used.
Most patients in our study used psycholeptic and psychoanaleptic medications (class 1). While the use of these medications may be appropriate for some older adults, potentially inappropriate use of these medications has been widely reported. 28 We distinguished a subgroup of patients with pain, using strong opioids (class 2). Yet, antiepileptic medications are also prescribed for the management of pain, particularly neuropathic pain, 18,19 but are not used by patients in class 2. As such, the class of antiepileptic users (class 3) may also include a considerable number of patients treated for pain. In particular, this could be the group of 26.6% of patients in this class using opioids.
But despite this probable overlap, antiepileptic users were more likely to be male compared with the total study population, suggesting that most antiepileptic medications were used to manage epilepsy rather than other symptoms or diseases, as epilepsy is more common in men than women aged 65 years and older. 29 We found a high proportion of males in the anti-Parkinson medication class (class 4), which is also in line with the national prevalence of Parkinson's disease. 30 The small number of antipsychotics in this class might indicate that it includes predominantly patients suffering from Parkinson's disease, as most antipsychotics are contraindicated in these patients. 31 The small number of antipsychotics in this class may actually reflect patients who have drug-induced Parkinsonism caused by antipsychotics. 
| Implications for practice
Our findings give insight into the extent of anticholinergic/sedative medication use and the different types of medications used that contribute to a high anticholinergic/sedative load. We found that the majority of patients with a high anticholinergic/sedative load used combinations of psycholeptic and psychoanaleptic medications. These medications are often inappropriately used among older adults, increasing the risk of medication related harm, such as falls and hospitalisation, and therefore should be considered for deprescribing where appropriate. 33, 34 So far however, few interventions have been effective in reducing a patient's anticholinergic/sedative load. In our recent randomised controlled trial, we found that medication reviews were not effective in reducing a high anticholinergic/sedative load among older community-dwelling patients. As a consequence, different strategies for identifying those patients who are in greatest need for medication optimisation and who could benefit from intervention are needed. 35 Targeting specific anticholinergic/sedative medications and tailoring interventions to specific subgroups of patients might be the most successful strategy to reduce the overall anticholinergic/sedative load.
| CONCLUSIONS
A large proportion of older adults in the Netherlands had a high anticholinergic/sedative load. Four distinct subgroups were identified.
Interventions aiming at reducing the overall anticholinergic/sedative load should be tailored to these subgroups.
